This is already starting to be implemented: in a current clinical trial of ALLO as a neuroprotector in AD (4 mg intravenous infusion, once per week, for a period of 12 months), ALLO was administered only to APOE ε4-positive AD patients aged 55 to 80 years. This evidence concerns the gene APOE and Alzheimer disease.